ArticleJournal of neurology2026
Does CANVAS mimic MSA-C? A prospective multimodal study.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAAGGG intronic expansions in RFC1 are responsible for Cerebellar ataxia, neuropathy, and vestibular areflexia syndrome (CANVAS), but also ataxia associated to dysautonomia, parkinsonism and pyramidal syndrome, creating clinical overlap with multiple system atrophy of cerebellar type (MSA-C).
objectivesThe aim of this study was to describe the natural history of RFC1-related ataxia, identify discriminative features compared to MSA-C, and study their survival outcomes.
methodsFrom clinical, imaging, and electrophysiological data of a French prospective cohort of 418 sporadic late-onset cerebellar ataxia, we extracted 65 MSA-C and 20 RFC1-related ataxia, and conducted cross-sectional and longitudinal analysis.
resultsEarlier age at onset, later parkinsonism, dysautonomia, pyramidal syndrome onset, and slower disease progression are significantly associated with RFC1-related ataxia (p < 0.05). Sensory impairment and chronic cough are key differentiating features. Median survival in RFC1-related ataxia is longer than 20 years (p < 0.0001).
conclusionRFC1-related ataxia is clinically distinguished from MSA-C by earlier onset, slower disease progression, and longer survival.
Indexed as
Identifiers
42616133What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.